VCA Stocks

Antisense Pharma GmbH, biotech leader in the development of targeted therapies for malignant tumors, receives venture capital amounting to EUR 27 million (USD 38 million).  Antisense Pharma is a pioneer in the development of antisense drugs. Discovered with the help of modern platform technology, the drugs effectively prevent disease-associated proteins to originate. This allows to tackle fatal diseases like cancer at their roots - fighting them causally rather than symptomatically.